Literature DB >> 11343206

Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens.

S Fournier1, C Rabian, C Alberti, M V Carmagnat, J F Garin, D Charron, F Derouin, J M Molina.   

Abstract

The in vitro lymphocyte proliferative response (LPR) and interferon (IFN)-gamma production in the presence of Toxoplasma antigen were evaluated in 97 human immunodeficiency virus (HIV)-1-infected patients with CD4 cell counts of <100 cells/microL (group 1), currently >300 cells/microL but previously <100 cells/microL (group 2), or always >300 cells/microL (group 3) and in 28 non-HIV-infected blood donors (group 4), all seropositive to Toxoplasma. In group 2, 81% of patients had a positive LPR, versus 20% in group 1 (P<10(-3)). IFN-gamma production was greater in group 2 than in group 1 (922 vs. 0 Deltapg/mL; P=10(-4)). Multivariate analysis found a significant association between a positive LPR to Toxoplasma antigen and a CD4 count >300 cells/microL (odds ratio [OR], 16.3; 95% confidence interval [CI], 5.3-50.2) and anti-Toxoplasma IgG titer >150 IU/mL (OR, 5; 95% CI, 1.6-15.2). Immune reconstitution under highly active antiretroviral therapy was associated with a restoration of immune responses against Toxoplasma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343206     DOI: 10.1086/320706

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Role of antiretroviral regimes in HIV-1 patients in reducing immune activation.

Authors:  Antonio Jiménez; Laura Molero; Ana Jiménez; Susana Castañón; Dolores Subirá; Miguel De Górgolas; Manuel Fedz-Guerrero; Rosa García
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

2.  Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy.

Authors:  Sergei Spitsin; Nancy B Tustin; Eric Riedel; Richard Tustin; Jennifer B Murray; Lauren M Peck; Mohammad Khan; Joseph Quinn; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

3.  B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease.

Authors:  Gaël Mouillot; Maryvonnick Carmagnat; Laurence Gérard; Jean-Luc Garnier; Claire Fieschi; Nicolas Vince; Lionel Karlin; Jean-François Viallard; Roland Jaussaud; Julien Boileau; Jean Donadieu; Martine Gardembas; Nicolas Schleinitz; Felipe Suarez; Eric Hachulla; Karen Delavigne; Martine Morisset; Serge Jacquot; Nicolas Just; Lionel Galicier; Dominique Charron; Patrice Debré; Eric Oksenhendler; Claire Rabian
Journal:  J Clin Immunol       Date:  2010-05-01       Impact factor: 8.317

4.  Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral Therapy Era.

Authors:  Hansjakob Furrer
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.663

Review 5.  Parasitic infections in HIV infected individuals: diagnostic & therapeutic challenges.

Authors:  Veeranoot Nissapatorn; Nongyao Sawangjaroen
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

6.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Authors:  J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann
Journal:  Infection       Date:  2013-09-14       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.